femasys inc making a differencein the lives of women one product at a time is a great privilege that drives the companys mission read more fembloc™ permanent contraceptive systemrevolutionizing family planning options for women read more the fembloc™ solution femasys is developing a permanent contraceptive solution fembloc™ that will provide a safe and effective family planning option for women who want to be free from temporary methods fembloc has been designed for widespread acceptance by physicians and their patients every gynecologist can perform inoffice simple nonsurgical placement using known intrauterine techniques safe and natural approach for patients pregnancy prevention by the body’s natural response to a temporary biopolymer with no intrusive implants or hormones least expensive convenient permanent option this office based procedure eliminates all extra costs to the practice and patient such as anesthesia hospitalequipment fees and radiology referrals fembloc™ permanent contraceptive system is not commercially available for sale  of all women using contraceptives no longer want more children   daniels k et al current contraceptive status among women aged  united states  national center for health statistics dec   jones j et al current contraceptive use in the united states  and changes in patterns of use since  national health statistics reports no  oct  products currently making a difference femasys has expanded options for women with its two commercially available products for diagnosis of infertility femvue® salineair device and cervical cancer femcerv® endocervical sampler about femvue the femvue® salineair device is used to introduce a consistent mixture of saline and air contrast in a controlled fashion for the tubal evaluation portion of the sono hsg the bright echoes of the air bubbles can be seen flowing into and through each fallopian tube providing physicians an effective contrast to make a tubal patency determination learn more about sono hsg sono hsg also called sonographic hysterosalpingogram is a transvaginal ultrasound technique that involves assessment of fallopian tube patency with a mixture of air and saline delivered through an intrauterine catheter as well as detection of abnormalities of the uterus learn more  gynecology in practice infertility edited by emre seli chapter  diagnosis and management of tubal factor infertility amanda n kallen and peter h kodamanspan   learn more about femcerv at wwwfemcervcom about us femasys inc is a privately held corporation committed to transforming womens healthcare worldwide by expanding options for women with innovative medical devices and next generation advancements providing significant clinical impact our products have been organically conceived researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the us food and drug administration fda per the requirements of  cfr  as well as iso  femasys has achieved significant milestones to date including numerous issued patents and filings clearance of multiple regulatory filings by the us fda european union canada and japan with other select countries in process our process  invent  develop  test  approve  build  market leadership kathy leesepsickpresident  ceo founder of femasys inc has served as president  ceo overseeing the development of the company since its inception she has over  years experience in medical device management directing product development operations and commercialization efforts in medical product regulated markets globally and is the inventor on more than  patents and patent applications jeffrey marcus md chief medical advisor practicing obstetrician gynecologist has influenced the company’s product development including intellectual property and commercialization efforts he has over  years of experience as a physician and was a founding member of atlanta womens health group he has served as a principal investigator of numerous clinical trials and as a member of medical advisory and speaker boards todd creechchief financial advisor has been involved since  and is responsible for overseeing the company’s financing accounting corporate development and investor activities he has over  years of experience where he has structured placed and managed capital investments raising millions in debt and equity financing for emerging companies such as zs pharma sarcode bioscience sirion therapeutics novaquest and centice also serves as a partner at healthquest capital daniel curriesenior vp operations has served as head of operations developing the companys infrastructure product development program and quality system foundation since its inception he has over  years of operational experience in the medical device industry working closely with research and development teams implementing and managing quality systems and developing fully compliant manufacturing operations both domestically and internationally lisa peacockvp regulatory affairs has served as vp overseeing global regulatory product approvals since  she has over  years of experience in medical device development compliance and global regulatory product approvals and has led product strategy and development initiatives for class iii medical devices that have successfully achieved pma approval and managed preclinical and quality aspects for groundbreaking technologies mimi zieman md vp clinical affairs has served as vp overseeing global clinical trial activities since  she has over  years of consulting experience in womens health and contraception medical education pharmacovigilance and clinical trial development she was the director of family planning for  years at grady memorial hospital and emory university where she founded a family planning fellowship program steven damon vp business  commercial development has served as vp since  overseeing strategic partnerships including distribution arrangements mr damon has over  years of experience in pharmaceutical and medical device business management in the us and europe with a track record of securing several key partnerships with pharmaceutical companies resulting in more than  million of nondilutive financing gary thompsonvp finance  administration has served as vp since  and has over  years of finance and management experience in the medical device and pharmaceutical industries and public accounting as a cpa for both growth and revenue generating stage companies he uniquely served as head of finance for a emerging unit within cr bard and was responsible for budgeting strategic plans and reporting tim pruittvp manufacturing has been involved since 7 and is responsible for overseeing the company’s manufacturing he has over  years of experience including machine design product development process engineering and operations for the manufacturing and distribution of medical devices and tissue products for companies such as cryolife cr bard aderans and novoste news dec  mar  dec  jul  apr  femasys appoints fred aslan and charles larsen to its board of directors atlanta ga march   femasys inc a developer of innovative medical devices for the womens healthcare market today announced that fred aslan founder and chief executive officer of advance medical inc and vice president of venrock and charles e larsen managing director of accuitive medical ventures have been appointed to the femasys board of directors both new directors bring significant leadership operations and commercial experience to femasys as the company prepares to commence its pivotal trial of fembloc™ which is designed to provide women with the first nonsurgical permanent contraception option delivered exclusively in the office read more femasys announces todd creech as chief financial officer atlanta ga december    femasys inc a developer of innovative medical devices for the womens healthcare market today announced the appointment of todd a creech as chief financial officer mr creech will serve as femasys principal financial and accounting officer will report to kathy leesepsick president and ceo and will be responsible for all financing accounting corporate development and investor activities read more femasys secures term loan facility from silicon valley bank atlanta ga july    femasys inc a developer of innovative medical devices for the womens healthcare market announced today that it has secured a term loan facility from silicon valley bank under the loan facility the company received initial funding and a conditional option to receive additional funding the company will use the funds for working capital as it supports the advancement of its groundbreaking nonsurgical female sterilization device read more femasys completes  million series b financing round atlanta ga april    femasys inc a developer of innovative medical devices for the womens healthcare market has raised a  million financing round the investor group was led by legacy capital partners and mario family partners the family offices of life sciences industry veterans john adams jr and dr ernest mario joining the companys board of directors is mr adams former ceo of adams respiratory therapeutics salem partners a los angeles based investment bank focused on life sciences advised the company on the transaction and participated as a principal investor read more femasys announces  million in series c financing to complete development of fembloc™ funding to support pivotal testing of nonsurgical permanent contraception solution fembloc™   ide approval granted by fda for us clinical trial of fembloc study to start early 7  atlanta dec   globe newswire  femasys inc a developer of innovative medical devices for the womens healthcare market today announced that it has closed  million in series c financing the transaction was arranged by salem partners a los angelesbased investment bank which also participated as a principal investor the series c syndicate included multiple institutional investors family offices and a multibilliondollar global medical device company the funding will be used primarily to support the pivotal testing of fembloc™ the companys revolutionary nonsurgical permanent contraception solution femasys designed fembloc to provide women with the first nonsurgical permanent contraceptive option delivered exclusively in the physicians office read more corporate contacts general information infofemasyscom employment hrfemasyscom business development steve damon  sdamonfemasyscom media  public relations jerry fink  jfinkfemasyscom femvue orders  customer service united states orders  femasys monfri  am   pm et toll free 77 customerservicefemasyscom fax  wwwfemvuecom japan orders  bayer healthcare bayer diagnostics japan femcerv orders  customer service united states  mckesson medicalsurgical toll free 7 wwwfemcervcom corporate headquarters femasys inc  johns creek court suite  suwanee ga  p  f  send message femasys announces todd creech as chief financial officer x atlanta ga  december    femasys inc a developer of innovative medical devices for the womens healthcare market today announced the appointment of todd a creech as chief financial officer mr creech will serve as femasys principal financial and accounting officer will report to kathy leesepsick president and ceo and will be responsible for all financing accounting corporate development and investor activities todd has a tremendous amount of financial and corporate development experience in the life sciences industry we are honored to welcome todd to the femasys team as we enter the next critical phase of growth while pursuing our vision of expanding healthcare options for women with our innovative medical devices said kathy leesepsick femasys president and ceo todds proven track record and financial leadership is exemplified by his success with numerous debt and equity financings to support the development of latestage programs regulatory approvals as well as commercial activities mr creech previously served as the chief financial officer of zs pharma inc from august  until june  and was part of the team responsible for taking the company public completing a successful secondary offering disseminating key clinical data and positioning the company for ma discussions and eventual acquisition during his tenure at zs pharma mr creech helped raise approximately  million in debt and equity financing prior to zs pharma mr creech was cfo and vice president of business development at sarcode bioscience where he led all financing legal accounting and corporate development activities shire pharmaceuticals acquired sarcode in april  prior to sarcode mr creech was cfo of sirion therapeutics an ophthalmic pharmaceutical company during his tenure he raised  million in debt and equity financing to support the development of six latestage clinical programs and two nda approvals and he also helped lead the sale of sirions drug assets to alcon and bausch  lomb mr creech worked with novaquest the investment group within quintiles inc where he structured placed and managed capital investments into usemerging biotech and specialty pharmaceutical companies prior to his work with novaquest he cofounded centice an optical sensor spin out from duke university in  mr creech has an additional  years of experience consulting to biotech and hightech companies while at sri international and andersen consulting mr creech holds bachelors degrees in finance and accounting from miami university of ohio and an mba from duke university this is an extremely exciting time to be joining femasys especially as the company prepares to commence its pivotal trial of fembloc™ which is designed to provide women with the first nonsurgical permanent contraception option delivered in exclusively in the office said mr creech i look forward to working closely with the femasys team to achieve its financial and strategic goals femasys secures term loan facility from silicon valley bank × atlanta ga july    femasys inc a developer of innovative medical devices for the womens healthcare market announced today that it has secured a term loan facility from silicon valley bank under the loan facility the company received initial funding and a conditional option to receive additional funding the company will use the funds for working capital as it supports the advancement of its groundbreaking nonsurgical female sterilization device we are pleased to build a relationship with silicon valley bank a leader in financial services for the healthcare industry this loan facility will provide greater financial flexibility as we aggressively pursue the regulatory milestones of our highly promising fembloc™ permanent contraceptive system and expansion of commercialization efforts for our novel medical devices remarked kathy leesepsick president  ceo of femasys inc the opportunity to work with innovative medical device companies like femasys is what excites us on the life science side of the svb portfolio said scott mccarty director of life science and healthcare for silicon valley banks atlanta office we have confidence in the femasys team and it has been a pleasure working with them throughout the implementation of the loan facility our partnership is intended to increase the companys probability of success as it develops and delivers solutions that are transforming womens healthcare femasys fills an important and significant gap in the womens healthcare continuum said john q adams jr legacy capital partners we believe that both physicians and patients will have great interest in the innovative new technologies and that we can provide value to the company through our highly experienced investor syndicate about silicon valley bank  wwwsvbcom for more than  years silicon valley bank svb has helped innovative companies and their investors move bold ideas forward fast svb provides targeted financial services and expertise through its offices in innovation centers around the world with commercial international and private banking services svb helps address the unique needs of innovators forbes named svb one of americas best banks  and one of americas bestmanaged companies  learn more at svbcom silicon valley bank is the california bank subsidiary and commercial banking operation of svb financial group nasdaq sivb and a member of the fdic silicon valley bank and svb financial group are members of the federal reserve system femasys completes  million series b financing round × atlanta ga april    femasys inc a developer of innovative medical devices for the womens healthcare market has raised a  million financing round the investor group was led by legacy capital partners and mario family partners the family offices of life sciences industry veterans john adams jr and dr ernest mario joining the companys board of directors is mr adams former ceo of adams respiratory therapeutics salem partners a los angeles based investment bank focused on life sciences advised the company on the transaction and participated as a principal investor femasys has developed a groundbreaking nonsurgical female sterilization device fembloc™ permanent contraceptive system that allows physicians to deliver exclusively in their office a biomaterial through a catheter based system to permanently block the fallopian tubes that substantially reduces patient risks and costs by eliminating the use of anesthesia and permanent implants the company has also expanded options for women with its two commercially available products for diagnosis of infertility femvue® salineair device and cervical cancer femcerv® endocervical sampler that present significant advantages for the patient physician and healthcare system we are pleased to have the support and confidence of this esteemed group of investors said kathy leesepsick femasys president and ceo this round of funding will enable femasys to invest in the people and programs necessary to achieve the investigational device exemption ide milestone for fembloc and expand commercialization globally for our diagnostic products to allow women access to better options when it comes to managing their health needs femasys fills an important and significant gap in the womens healthcare continuum said john q adams jr legacy capital partners we believe that both physicians and patients will have great interest in the innovative new technologies and that we can provide value to the company through our highly experienced investor syndicate about legacy capital partners john adams jr was the former ceo of adams respiratory therapeutics developer of the mucinex brands adams was sold to reckitt benckiser in  for  billion mr adams has been in the pharmaceutical industry for over  years and has made investments in a number of developmentstage companies legacy capital partners is based in southlake tx about mario family partners mario family partners is the private equity arm of dr ernest marios family office dr mario was the former ceo of alza corporation which was sold to johnson  johnson for  billion in  the largestever ma deal for jj at the time he was previously ceo of glaxo and currently sits on the boards of boston scientific corporation and celgene corporation among others about salem partners llc  wwwsalempartnerscom salem partners is a boutique investment bank and wealth management firm based in los angeles that specializes in raising growth capital and executing ma assignments for companies in the media life sciences and industrial sectors salem has a strong track record in life sciences having raised substantially all of the private capital for adams respiratory therapeutics zs pharma inc and neos therapeutics femasys appoints fred aslan and charles larsen to its board of directors ×  aslan and larsen are seasoned healthcare executives who have successfully developed emerging technologies to advance the practice of medicine  atlanta ga march    femasys inc a developer of innovative medical devices for the womens healthcare market today announced that fred aslan founder and chief executive officer of advance medical inc and vice president of venrock and charles e larsen managing director of accuitive medical ventures have been appointed to the femasys board of directors both new directors bring significant leadership operations and commercial experience to femasys as the company prepares to commence its pivotal trial of fembloc™ which is designed to provide women with the first nonsurgical permanent contraception option delivered exclusively in the office we are extremely honored to have fred and charlie join our board of directors – they are proven executives who have been successful starting new businesses developing and commercializing emerging technologies building organizations and delivering value to shareholders” said kathy leesepsick president and ceo of femasys “their considerable experience will be invaluable to our team as we embark on the next phase of development with fembloc™” dr aslan has over  years of strategic management and direct investment experience in the medical device diagnostics and biotechnology sectors dr aslan is currently the founder and chief executive officer of advance medical a venrock portfolio company that is focused on the commercialization of medical device and diagnostics technologies in brazil and he is also a vice president at venrock dr aslan has served on the board of directors of receptos a company recently acquired by celgene and has been a board observer for a number of other companies including zeltiq and powervision dr aslan was the director of business development and investor relations at curagen corporation prior to curagen he worked at boston consulting group where he advised biotechnology and pharmaceutical companies on a number of strategic initiatives dr aslan received his bs in biology from duke university md from yale university school of medicine and mba from the harvard business school mr larsen has over  years of operating and technical experience in the medical device industry he cofounded novoste corporation and the innovation factory and through his role at the innovation factory he cofounded additional companies including acufocus aquesys halscion liposonix neuronetics and sebacia he holds over  issued us and international patents on medical devices before joining novoste mr larsen held positions with novoste puerto rico cordis corporation key pharmaceuticals and parkedaviswarner lambert in executive senior engineering and project management roles mr larsen received a bs in mechanical engineering from the new jersey institute of technology mr larsen currently is member of the board of directors for acufocus cardiofocus intuity and torax about femasys femasys inc based in atlanta ga is a privately held corporation committed to transforming womens healthcare worldwide by expanding options for women with innovative medical devices and next generation advancements providing significant clinical impact additional information about femasys and the company’s products can be found at wwwfemasyscom femasys has developed a groundbreaking nonsurgical female sterilization device fembloc™ permanent contraceptive system that allows physicians to deliver exclusively in their office a biopolymer through a catheterbased delivery system to permanently block the fallopian tubes in a procedure that substantially reduces patient risks and costs by eliminating the use of anesthesia and permanent implants the company has also expanded options for women with its two commercially available products for diagnosis of infertility femvue® salineair device and cervical cancer femcerv® endocervical sampler that present significant advantages for the patient physician and healthcare system femasys announces  million in series c financing to complete development of fembloc™ funding to support pivotal testing of nonsurgical permanent contraception solution fembloc™   ide approval granted by fda for us clinical trial of fembloc study to start early 7  × atlanta dec   globe newswire  femasys inc a developer of innovative medical devices for the womens healthcare market today announced that it has closed  million in series c financing the transaction was arranged by salem partners a los angelesbased investment bank which also participated as a principal investor the series c syndicate included multiple institutional investors family offices and a multibilliondollar global medical device company the funding will be used primarily to support the pivotal testing of fembloc™ the companys revolutionary nonsurgical permanent contraception solution femasys designed fembloc to provide women with the first nonsurgical permanent contraceptive option delivered exclusively in the physicians office we are thrilled with the level of enthusiasm in this oversubscribed round of funding and grateful for the backing from our new and existing investors said kathy leesepsick femasys president and ceo their financial investment enables us to conduct and complete the fembloc clinical plan which will support our planned premarket approval application pma and ultimately our vision of improving the lives of women by providing access to an ideal permanent contraception solution that is safe and highly effective for women in the us and worldwide femasys also announced that it has gained us food and drug administration fda investigational device exemption ide approval to launch a prospective multicenter clinical trial to evaluate the safety of the fembloc permanent contraceptive system while preventing pregnancy the clinical trial which will enroll women who desire permanent birth control by occlusion of the fallopian tubes will be the companys first trial to evaluate the complete fembloc contraceptive system for its intended use fembloc is designed to fill the unmet need of a safe permanent contraceptive method that can be easily implemented since it does not require specialized surgical skills or investment in costly surgical equipment said mimi zieman md vice president of clinical affairs at femasys and a board certified obgyn specializing in family planning this contrasts with current female sterilization options that have the inconvenience and risks associated with surgery and anesthesia for tubal ligation and for hysteroscopic procedures  the challenge of placing the devices correctly and concerns with longterm use dechert llp served as legal counsel to femasys inc while baker botts llp served as investor counsel about femasys femasys is a privately held corporation committed to transforming womens healthcare worldwide by expanding options for women with innovative medical devices and next generation advancements providing significant clinical impact additional information about femasys and the companys products can be found at wwwfemasyscom femasys has developed a groundbreaking nonsurgical female sterilization solution fembloc™ permanent contraceptive system that allows physicians to deliver exclusively in their office a biopolymer through a catheterbased delivery system to permanently block the fallopian tubes in a procedure that substantially reduces patient risks and costs by eliminating the use of anesthesia and permanent implants the company has also expanded options for women with its two commercially available products for diagnosis of infertility femvue® salineair device and cervical cancer femcerv® endocervical sampler that present significant advantages for the patient physician and healthcare system fembloc permanent contraceptive system is not commercially available for sale femasys fembloc femvue and femcerv are registered trademarks of femasys inc all rights reserved terms  privacy × this site and any related services are provided subject to these terms and conditions please read the following information carefully your continued use of this website will indicate your agreement to be bound by the terms and conditions set forth belowif you do not wish to be bound by these terms and conditions please do not use or access this website femasys may modify the terms and conditions at any time and such modifications will be effective immediately upon posting to the website please review the terms of use and privacy policy each time you visit the femasys website purpose this is a world wide web site for information about femasys inc products fembloc femcerv and femvue and sono hsg the purpose is to provide information to healthcare providers patients and all interested parties copyright all rights including copyright in the content of the web pages contained in this website are owned or controlled for these purposes by femasys inc in accessing femasys web pages you agree that you may only download the content for your personal noncommercial use you are not permitted to copy reproduce republish distribute broadcast download store in any medium transmit show or play in public adapt or change in any way the content of these femasys web pages for any other purpose whatsoever without the prior written permission of femasys inc security unauthorized attempts to upload information or change information on this web site are strictly prohibited and may be punishable under the computer fraud and abuse act of  and the national information infrastructure protection act for site security purposes and to ensure that this service remains available to all users this server employs software programs to monitor network traffic to identify unauthorized attempts to upload or change information or otherwise cause damage trademark notice femasys is a trademark of femasys inc other trademarks logos brand names and slogans registered or used by femasys in the united states andor other countries include but are not limited to the following fembloc femcerv femchec femaseed and femvue all other trademarks and registered trademarks are the property of their respective owners privacy policyexcept to maintain required correspondence files no other attempts are made to identify individual users or their usage habits raw data logs are used to determine how many users are accessing the site which pages are most popular and from time to time from which top level domain users are coming no personally identifying information about you will be obtained when you visit this site unless you choose to provide such information to us if you choose to send an email to points of contact on the site any information you provide will be used solely to respond to your request femasys  products fembloc permanent contraceptive system designed to permanently block a womans fallopian tubes in a simple costeffective and convenient inoffice procedure fembloc utilizes standard catheter techniques and a degradable biomaterial to block the tubes without the use of permanent implants • requires pma approval femvue salineair device allows for an infertility diagnosis of a womans fallopian tubes in the gynecologists office using existing ultrasound femvue expands services with a more costeffective and convenient procedure • k cleared ce marked for the eu canada licensed japan registered • distributed in the us by smith  nephew and in japan by bayer healthcare femchec mini pressure management device ensures low pressure is maintained during the confirmation test for blocked fallopian tubes after permanent sterilization providing confidence for this essential us mandated test • k cleared and ce marked for the eu femcerv endocervical sampler minimizes the risk of incomplete sampling of the endocervical canal and optimizes diagnostic acuity by collecting a complete ° sample for cancer diagnosis • k cleared and ce marked for the eu femaseed insemination catheter  designed to direct sperm to each fallopian tube where conception occurs to possibly improve pregnancy rates • k clearance and ce mark pending     femaseed and fembloc are currently not approved for sale in the us        7 femasys inc all rights reserved terms  privacy femasys inc  product pipeline analysis  update sales and support     uk  7 7  us infomarketpublisherscom business  finance retail retail consumer goods food  beverage industry chemicals it  technology life sciences services about faq my cart market reports pressreleases events about us terms  conditions customer faq market research reports company reports femasys inc  product pipeline analysis  update date november   pages  price us 7 license  single user price  us 7 site license price  us  enterprisewide price global site license  us  publisher globaldata report type strategic report delivery email delivery pdf id fbcfabden leaflet download pdf leaflet abstracts contents list of tables list of figures summaryfemasys inc femasys is a medical device company that offers medical device solutions for women’s healthcare the company offers products for permanent contraception infertility solutions and cancer diagnosis its products include fembloc permanent contraceptive system femvue salineair device and femcerv endocervical sampler femasys’s permanent contraceptive system is designed to permanently block the fallopian tubes in an innovative nonsurgical approach the company’s insemination catheter is designed for directed delivery of washed spermatozoa to fallopian tubes for artificial insemination it offers endocervical sampler designed for sampling of the uterine cavity for cancer diagnosis femasys is headquartered in suwanee georgia the usthis report is a source for data analysis and actionable intelligence on the company’s portfolio of pipeline products the report provides key information about the company its major products and brands the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantagescopethe report reviews detailed company profile with information on business description key company facts major products and services key competitors key employees locations and subsidiaries and recent developmentsthe report analyzes all pipeline products in development for the company femasys incthe report provides pipeline analysis on all pipeline products of the company by equipment type by indication by development stage and by trial statusthe report covers detailed information on each pipeline product with information on pipeline territory stage of development device class regulatory path indications applications and estimated launch datethe report provides detailed description of products in development technical specification and functionsthe report also covers ongoing clinical trials wherever applicable with information on trial name trial objective sponsor trial design trial status and phase estimated start and end datereasons to buydevelop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscapedesign and develop your product development marketing and sales strategies by understanding the competitor portfolioto formulate effective research  development strategiesdevelop marketentry and market expansion strategiesexploit inlicensing and outlicensing opportunities by identifying products most likely to ensure a robust returnplan mergers and acquisitions effectively by identifying key players of the most promising pipeline identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantagedevelop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials stage and of development etcidentify understand and capitalize the next highvalue products that your competitor would add in its portfolio femasys inc company snapshotfemasys inc company overviewkey informationfemasys inc pipeline products and clinical trials overviewfemasys inc  major products and servicesfemasys inc pipeline products by development stagefemasys inc pipeline products overviewfemaseed insemination catheterfemaseed insemination catheter product overviewfembloc permanent contraceptive systemfembloc permanent contraceptive system product overviewfemcav endometrial samplerfemcav endometrial sampler product overviewfemasys inc  key competitorsfemasys inc  key employeesfemasys inc  locations and subsidiarieshead officerecent developmentsfemasys inc recent developmentsjul   femasys secures term loan facility from silicon valley bankjul   femasys signs distribution agreement with mckesson medicalsurgical for femcerv device for diagnosis of cervical canceroct   smith  nephew expands uterine care portfolio with innovative diagnostic deviceapr   femasys launches femcerv endocervical samplerjan   femasys receives fda k clearance for endocervical samplerjun   ge capital closes m multidraw term loan facility for femasysnov 7  femasys receives fda k clearance for femchec pressure management deviceaug   femasys and norgenix announce distribution agreement for femvue salineair device for infertility diagnosismay   femasys announces fda k clearance of femvue salineair device for inoffice diagnostic sono hsg test for evaluating fallopian tubesappendixmethodologyabout globaldatacontact usdisclaimer list of tablesfemasys inc key factsfemasys inc pipeline products and clinical trials overviewfemasys inc pipeline products by equipment typefemasys inc pipeline products by indicationfemasys inc major products and servicesfemasys inc number of pipeline products by development stagefemasys inc pipeline products summary by development stagefemaseed insemination catheter  product statusfemaseed insemination catheter  product descriptionfembloc permanent contraceptive system  product statusfembloc permanent contraceptive system  product descriptionfemcav endometrial sampler  product statusfemcav endometrial sampler  product descriptionfemasys inc key employees list of figuresfemasys inc pipeline products by equipment typefemasys inc pipeline products by development stage skip to top more publications neuro kinetics inc  product pipeline analysis  update us 7 jun  ·  pages eci biotech inc  product pipeline analysis  update us 7 jun  ·  pages ceres nanosciences inc  product pipeline analysis  update us 7 oct  ·  pages eqalix inc  product pipeline analysis  update us 7 oct  ·  pages mc inc  product pipeline analysis  update us 7 nov  ·  pages ask your question femasys inc  product pipeline analysis  update company name contact person phonefax email request invoice your enquiry please click on a check box below to confirm you are not a robot market reports all categories sales and support      7 7  infomarketpublisherscom   marketpublisherscom about us our clients our publishers customer faq market reports new publications reports by regions pressreleases terms  conditions privacy policy return policy affiliate program join as publisher follow us femasys inc company profile  bloomberg feedback femasys inc private company company profile sector health care industry medical equipment  devices subindustry medical equipment femasys inc is a medical device company the company researches develops and manufactures womens healthcare medical devices for use in physicians offices corporate information address  research court suite  suwanee ga  united states phone  fax  from the web key executives kathy leesepsick presidentceo sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data femasys  news home company about leadership products permanent contraception infertility solutions cancer diagnosis partnerships investor news login contact femasys signs distribution agreement with mckesson medicalsurgical for femcerv device for diagnosis of cervical cancer atlanta ga july   pr newswire femasys inc an emerging medical device developer of womens healthcare solutions announced today that it has entered into a nationwide distribution agreement with mckesson medicalsurgical to sell and distribute femasys femcerv™ endocervical sampler femcerv collects a tissue sample of a womans endocervical canal for histological analysis when cervical cancer is suspected under terms of the agreement mckesson medicalsurgical will sell and distribute the femcerv device nationwide through its sales force kathy leesepsick president  ceo of femasys commented we are thrilled to create an alliance with mckesson medicalsurgical in bringing femcerv to the market as a novel new advancement in tissue sample collection for cervical cancer diagnosis with mckesson medicalsurgicals extensive market presence physicians will gain access across the country to this much needed technology that has been designed with the woman and her anatomy in mind clinical data has demonstrated that physicians find femcerv easy to insert and well tolerated by almost all patients who experienced mild or no discomfort were pleased to offer femasys femcerv product to our customers said joan eliasek senior vice president supplier management mckesson medicalsurgical as a company we are in business for one reason better health and fighting cancer is a major aspect of better health in our country we are glad to offer products to our customers that help them deliver better care for their patients about femcerv femcerv is intended for women who have received an abnormal pap smear result or have other factors that require a sampling of her cervical canal ie cervical lesions extending into the canal or when there is undiagnosed uterine bleeding the device minimizes the risk of incomplete sampling and optimizes diagnostic acuity by collecting a complete ° sample while protecting the sample from contamination endocervical curettage has the potential to decrease the number of unnecessary surgical treatments and to play a role in reducing the number of undiagnosed cases of cervical cancer for additional information on the femcerv device please visit wwwfemcervcom about mckesson mckesson medicalsurgicals parent mckesson corporation currently ranked th on the fortune  list is a healthcare services and information technology company dedicated to making the business of healthcare run better mckesson medicalsurgical works with payers hospitals physician offices pharmacies pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting mckesson medicalsurgical helps its customers improve their financial operational and clinical performance with solutions that include pharmaceutical and medicalsurgical supply management healthcare information technology and business and clinical services for more information about mckesson visit wwwmckessoncom back to news    7 femasys inc all rights reserved terms  privacy femasys company profile  owler we just sent you an email to verify your account check your inbox     resend verification link  sign in sign in sign up you have just joined  femasys completes  million series b financing round femasys completes  million series b financing round apr    et from femasys inc femasys inc     facebook twitter pinterest femasys inc atlanta april   prnewswire  femasys inc a developer of innovative medical devices for the womens healthcare market has raised a  million financing round  the investor group was led by legacy capital partners and mario family partners the family offices of life sciences industry veterans john adams jr and dr ernest mario joining the companys board of directors is mr adams former ceo of adams respiratory therapeutics  salem partners a los angeles based investment bank focused on life sciences advised the company on the transaction and participated as a principal investor femasys has developed a groundbreaking nonsurgical female sterilization device fembloc™ permanent contraceptive system that allows physicians to deliver exclusively in their office a biomaterial through a catheter based system to permanently block the fallopian tubes that substantially reduces patient risks and costs by eliminating the use of anesthesia and permanent implants  the company has also expanded options for women with its two commercially available products for diagnosis of infertility femvue® salineair device and cervical cancer femcerv® endocervical sampler that present significant advantages for the patient physician and healthcare system    we are pleased to have the support and confidence of this esteemed group of investors said kathy leesepsick femasys president and ceo this round of funding will enable femasys to invest in the people and programs necessary to achieve the investigational device exemption ide milestone for fembloc and expand commercialization globally for our diagnostic products to allow women access to better options when it comes to managing their health needs femasys fills an important and significant gap in the womens healthcare continuum said john q adams jr legacy capital partners we believe that both physicians and patients will have great interest in the innovative new technologies and that we can provide value to the company through our highly experienced investor syndicate about femasys inc  wwwfemasyscom  femasys inc based in atlanta ga is a privately held corporation committed to advancing womens healthcare worldwide by expanding options for women with innovative medical devices and next generation advancements providing significant clinical impact  additional information about femasys and the companys products can be found at wwwfemasyscom about legacy capital partners john adams jr was the former ceo of adams respiratory therapeutics developer of the mucinex brands adams was sold to reckitt benckiser in  for  billion  mr adams has been in the pharmaceutical industry for over  years and has made investments in a number of developmentstage companies  legacy capital partners is based in southlake tx about mario family partners mario family partners is the private equity arm of dr ernest marios family office  dr mario was the former ceo of alza corporation which was sold to johnson  johnson for  billion in  the largestever ma deal for jj at the time  he was previously ceo of glaxo and currently sits on the boards of boston scientific corporation and celgene corporation among others about salem partners llc  wwwsalempartnerscom salem partners is a boutique investment bank and wealth management firm based in los angeles that specializes in raising growth capital and executing ma assignments for companies in the media life sciences and industrial sectors  salem has a strong track record in life sciences having raised substantially all of the private capital for adams respiratory therapeutics zs pharma inc and neos therapeutics femasys fembloc femvue and femcerv are registered trademarks of femasys inc  all rights reserved media contact             jerry fink  logo  httpphotosprnewswirecomprnhcllogo  source femasys inc related links httpwwwfemasyscom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more jul   7 et preview femasys secures term loan facility from silicon valley bank jul    et preview femasys signs distribution agreement with mckesson medicalsurgical for femcerv device for diagnosis of cervical cancer my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search femasys inc  suwanee  ga  company information products resources my account talk to a db advisor 7 business directory ga suwanee surgical appliances and supplies manufacturing  implants surgical femasys inc f femasys inc claim this business  johns creek ct   suwanee ga  get directions   wwwfemasyscom business info founded  incorporated annual revenue  employee count  industries manufacturing  implants surgical contacts kathy leesepsick contact business your email address subject message send message company summary femasys inc is located at  johns creek ct   in suwanee and has been in the business of manufacturing  implants surgical since  verified status unverified address unverified last verified  phone unverified payment method unverified view full report similar businesses nearby our similar businesses nearby shows similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile competitive landscape our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile payments accepted no data hours sunday   monday   tuesday   wednesday   thursday   friday   saturday   f view additional data select from over  networks below to view available data about this business if this data is unavailable or inaccurate and you own or represent this business click here for more information on how you may be able to correct it credibility review google facebookcom yellowbookcom bingcom yellowpagescom merchantcircle tele atlas tomtom twittercom aol mapquest yahoo local applesiri groupon hotfrogcom comcastnet search reachlocal admedia dealsplus shoptopiacom alteryx dogtime media kslcom sirtune americantownscom driverside kudzucom specialsagentcom answerscom egood lawinfocom spotlikescom anywhocom egumball likenesscom spotzot eservicelog mapmyrun technocom apartmentguidecom ezlocalcom eztousecom teleroute aroundmecom metropolistcom therapistscom atlanta newhomes findlawcom time out new york avantar findthebestcom mojopagescom bb yellowpages fivestar software mycitywaycom tripadvisor bckyrdcom giftcardscom mycouponscom beachcaliforniacom golocal7com mymovecom upmesocialcom belo goodinfo newsgazette nokia usdirectorycom carscom nomao centzycom hibu openlistcom chacha search homeplatecom ownlocalcom visikard challamacom homestore patchcom voltari citybot pelopidas vouchd classifiedads hostway placeiq walkscorecom cloudmade hoodoyou planetdiscovercom weddingwirecom powerprofiles where inc contractorscom igolocalcom radiate media wikiocity couponmap indeedcom wimgocom crowdspot innova electronics intellistrand realtorcom datasphere inthemocom replycom yellowbotcom jiwire rocket fuel yellowpagecitycom dmvorg justclicklocalcom dirxion keencom zidstercom photos business credit report receive a onetime comprehensive credit report on this company get full credit report facebook twitter yelp call 7 to speak with a db advisor today customer resources products education center business articles  insights glossary contact us customer support communication preferences search for db duns our company about us company history business credit history careers press releases news success stories hoovers our network partners affiliates blog access to capital entrepreneurial initiative db international supplieredge site links business directory site map pipeda privacy policy website terms of service product license agreement  dun  bradstreet inc 7 all rights reserved femasys inc making a differencein the lives of women one product at a time is a great privilege that drives the companys mission read more fembloc™ permanent contraceptive systemrevolutionizing family planning options for women read more the fembloc™ solution femasys is developing a permanent contraceptive solution fembloc™ that will provide a safe and effective family planning option for women who want to be free from temporary methods fembloc has been designed for widespread acceptance by physicians and their patients every gynecologist can perform inoffice simple nonsurgical placement using known intrauterine techniques safe and natural approach for patients pregnancy prevention by the body’s natural response to a temporary biopolymer with no intrusive implants or hormones least expensive convenient permanent option this office based procedure eliminates all extra costs to the practice and patient such as anesthesia hospitalequipment fees and radiology referrals fembloc™ permanent contraceptive system is not commercially available for sale  of all women using contraceptives no longer want more children   daniels k et al current contraceptive status among women aged  united states  national center for health statistics dec   jones j et al current contraceptive use in the united states  and changes in patterns of use since  national health statistics reports no  oct  products currently making a difference femasys has expanded options for women with its two commercially available products for diagnosis of infertility femvue® salineair device and cervical cancer femcerv® endocervical sampler about femvue the femvue® salineair device is used to introduce a consistent mixture of saline and air contrast in a controlled fashion for the tubal evaluation portion of the sono hsg the bright echoes of the air bubbles can be seen flowing into and through each fallopian tube providing physicians an effective contrast to make a tubal patency determination learn more about sono hsg sono hsg also called sonographic hysterosalpingogram is a transvaginal ultrasound technique that involves assessment of fallopian tube patency with a mixture of air and saline delivered through an intrauterine catheter as well as detection of abnormalities of the uterus learn more  gynecology in practice infertility edited by emre seli chapter  diagnosis and management of tubal factor infertility amanda n kallen and peter h kodamanspan   learn more about femcerv at wwwfemcervcom about us femasys inc is a privately held corporation committed to transforming womens healthcare worldwide by expanding options for women with innovative medical devices and next generation advancements providing significant clinical impact our products have been organically conceived researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the us food and drug administration fda per the requirements of  cfr  as well as iso  femasys has achieved significant milestones to date including numerous issued patents and filings clearance of multiple regulatory filings by the us fda european union canada and japan with other select countries in process our process  invent  develop  test  approve  build  market leadership kathy leesepsickpresident  ceo founder of femasys inc has served as president  ceo overseeing the development of the company since its inception she has over  years experience in medical device management directing product development operations and commercialization efforts in medical product regulated markets globally and is the inventor on more than  patents and patent applications jeffrey marcus md chief medical advisor practicing obstetrician gynecologist has influenced the company’s product development including intellectual property and commercialization efforts he has over  years of experience as a physician and was a founding member of atlanta womens health group he has served as a principal investigator of numerous clinical trials and as a member of medical advisory and speaker boards todd creechchief financial advisor has been involved since  and is responsible for overseeing the company’s financing accounting corporate development and investor activities he has over  years of experience where he has structured placed and managed capital investments raising millions in debt and equity financing for emerging companies such as zs pharma sarcode bioscience sirion therapeutics novaquest and centice also serves as a partner at healthquest capital daniel curriesenior vp operations has served as head of operations developing the companys infrastructure product development program and quality system foundation since its inception he has over  years of operational experience in the medical device industry working closely with research and development teams implementing and managing quality systems and developing fully compliant manufacturing operations both domestically and internationally lisa peacockvp regulatory affairs has served as vp overseeing global regulatory product approvals since  she has over  years of experience in medical device development compliance and global regulatory product approvals and has led product strategy and development initiatives for class iii medical devices that have successfully achieved pma approval and managed preclinical and quality aspects for groundbreaking technologies mimi zieman md vp clinical affairs has served as vp overseeing global clinical trial activities since  she has over  years of consulting experience in womens health and contraception medical education pharmacovigilance and clinical trial development she was the director of family planning for  years at grady memorial hospital and emory university where she founded a family planning fellowship program steven damon vp business  commercial development has served as vp since  overseeing strategic partnerships including distribution arrangements mr damon has over  years of experience in pharmaceutical and medical device business management in the us and europe with a track record of securing several key partnerships with pharmaceutical companies resulting in more than  million of nondilutive financing gary thompsonvp finance  administration has served as vp since  and has over  years of finance and management experience in the medical device and pharmaceutical industries and public accounting as a cpa for both growth and revenue generating stage companies he uniquely served as head of finance for a emerging unit within cr bard and was responsible for budgeting strategic plans and reporting tim pruittvp manufacturing has been involved since 7 and is responsible for overseeing the company’s manufacturing he has over  years of experience including machine design product development process engineering and operations for the manufacturing and distribution of medical devices and tissue products for companies such as cryolife cr bard aderans and novoste news dec  mar  dec  jul  apr  femasys appoints fred aslan and charles larsen to its board of directors atlanta ga march   femasys inc a developer of innovative medical devices for the womens healthcare market today announced that fred aslan founder and chief executive officer of advance medical inc and vice president of venrock and charles e larsen managing director of accuitive medical ventures have been appointed to the femasys board of directors both new directors bring significant leadership operations and commercial experience to femasys as the company prepares to commence its pivotal trial of fembloc™ which is designed to provide women with the first nonsurgical permanent contraception option delivered exclusively in the office read more femasys announces todd creech as chief financial officer atlanta ga december    femasys inc a developer of innovative medical devices for the womens healthcare market today announced the appointment of todd a creech as chief financial officer mr creech will serve as femasys principal financial and accounting officer will report to kathy leesepsick president and ceo and will be responsible for all financing accounting corporate development and investor activities read more femasys secures term loan facility from silicon valley bank atlanta ga july    femasys inc a developer of innovative medical devices for the womens healthcare market announced today that it has secured a term loan facility from silicon valley bank under the loan facility the company received initial funding and a conditional option to receive additional funding the company will use the funds for working capital as it supports the advancement of its groundbreaking nonsurgical female sterilization device read more femasys completes  million series b financing round atlanta ga april    femasys inc a developer of innovative medical devices for the womens healthcare market has raised a  million financing round the investor group was led by legacy capital partners and mario family partners the family offices of life sciences industry veterans john adams jr and dr ernest mario joining the companys board of directors is mr adams former ceo of adams respiratory therapeutics salem partners a los angeles based investment bank focused on life sciences advised the company on the transaction and participated as a principal investor read more femasys announces  million in series c financing to complete development of fembloc™ funding to support pivotal testing of nonsurgical permanent contraception solution fembloc™   ide approval granted by fda for us clinical trial of fembloc study to start early 7  atlanta dec   globe newswire  femasys inc a developer of innovative medical devices for the womens healthcare market today announced that it has closed  million in series c financing the transaction was arranged by salem partners a los angelesbased investment bank which also participated as a principal investor the series c syndicate included multiple institutional investors family offices and a multibilliondollar global medical device company the funding will be used primarily to support the pivotal testing of fembloc™ the companys revolutionary nonsurgical permanent contraception solution femasys designed fembloc to provide women with the first nonsurgical permanent contraceptive option delivered exclusively in the physicians office read more corporate contacts general information infofemasyscom employment hrfemasyscom business development steve damon  sdamonfemasyscom media  public relations jerry fink  jfinkfemasyscom femvue orders  customer service united states orders  femasys monfri  am   pm et toll free 77 customerservicefemasyscom fax  wwwfemvuecom japan orders  bayer healthcare bayer diagnostics japan femcerv orders  customer service united states  mckesson medicalsurgical toll free 7 wwwfemcervcom corporate headquarters femasys inc  johns creek court suite  suwanee ga  p  f  send message femasys announces todd creech as chief financial officer x atlanta ga  december    femasys inc a developer of innovative medical devices for the womens healthcare market today announced the appointment of todd a creech as chief financial officer mr creech will serve as femasys principal financial and accounting officer will report to kathy leesepsick president and ceo and will be responsible for all financing accounting corporate development and investor activities todd has a tremendous amount of financial and corporate development experience in the life sciences industry we are honored to welcome todd to the femasys team as we enter the next critical phase of growth while pursuing our vision of expanding healthcare options for women with our innovative medical devices said kathy leesepsick femasys president and ceo todds proven track record and financial leadership is exemplified by his success with numerous debt and equity financings to support the development of latestage programs regulatory approvals as well as commercial activities mr creech previously served as the chief financial officer of zs pharma inc from august  until june  and was part of the team responsible for taking the company public completing a successful secondary offering disseminating key clinical data and positioning the company for ma discussions and eventual acquisition during his tenure at zs pharma mr creech helped raise approximately  million in debt and equity financing prior to zs pharma mr creech was cfo and vice president of business development at sarcode bioscience where he led all financing legal accounting and corporate development activities shire pharmaceuticals acquired sarcode in april  prior to sarcode mr creech was cfo of sirion therapeutics an ophthalmic pharmaceutical company during his tenure he raised  million in debt and equity financing to support the development of six latestage clinical programs and two nda approvals and he also helped lead the sale of sirions drug assets to alcon and bausch  lomb mr creech worked with novaquest the investment group within quintiles inc where he structured placed and managed capital investments into usemerging biotech and specialty pharmaceutical companies prior to his work with novaquest he cofounded centice an optical sensor spin out from duke university in  mr creech has an additional  years of experience consulting to biotech and hightech companies while at sri international and andersen consulting mr creech holds bachelors degrees in finance and accounting from miami university of ohio and an mba from duke university this is an extremely exciting time to be joining femasys especially as the company prepares to commence its pivotal trial of fembloc™ which is designed to provide women with the first nonsurgical permanent contraception option delivered in exclusively in the office said mr creech i look forward to working closely with the femasys team to achieve its financial and strategic goals femasys secures term loan facility from silicon valley bank × atlanta ga july    femasys inc a developer of innovative medical devices for the womens healthcare market announced today that it has secured a term loan facility from silicon valley bank under the loan facility the company received initial funding and a conditional option to receive additional funding the company will use the funds for working capital as it supports the advancement of its groundbreaking nonsurgical female sterilization device we are pleased to build a relationship with silicon valley bank a leader in financial services for the healthcare industry this loan facility will provide greater financial flexibility as we aggressively pursue the regulatory milestones of our highly promising fembloc™ permanent contraceptive system and expansion of commercialization efforts for our novel medical devices remarked kathy leesepsick president  ceo of femasys inc the opportunity to work with innovative medical device companies like femasys is what excites us on the life science side of the svb portfolio said scott mccarty director of life science and healthcare for silicon valley banks atlanta office we have confidence in the femasys team and it has been a pleasure working with them throughout the implementation of the loan facility our partnership is intended to increase the companys probability of success as it develops and delivers solutions that are transforming womens healthcare femasys fills an important and significant gap in the womens healthcare continuum said john q adams jr legacy capital partners we believe that both physicians and patients will have great interest in the innovative new technologies and that we can provide value to the company through our highly experienced investor syndicate about silicon valley bank  wwwsvbcom for more than  years silicon valley bank svb has helped innovative companies and their investors move bold ideas forward fast svb provides targeted financial services and expertise through its offices in innovation centers around the world with commercial international and private banking services svb helps address the unique needs of innovators forbes named svb one of americas best banks  and one of americas bestmanaged companies  learn more at svbcom silicon valley bank is the california bank subsidiary and commercial banking operation of svb financial group nasdaq sivb and a member of the fdic silicon valley bank and svb financial group are members of the federal reserve system femasys completes  million series b financing round × atlanta ga april    femasys inc a developer of innovative medical devices for the womens healthcare market has raised a  million financing round the investor group was led by legacy capital partners and mario family partners the family offices of life sciences industry veterans john adams jr and dr ernest mario joining the companys board of directors is mr adams former ceo of adams respiratory therapeutics salem partners a los angeles based investment bank focused on life sciences advised the company on the transaction and participated as a principal investor femasys has developed a groundbreaking nonsurgical female sterilization device fembloc™ permanent contraceptive system that allows physicians to deliver exclusively in their office a biomaterial through a catheter based system to permanently block the fallopian tubes that substantially reduces patient risks and costs by eliminating the use of anesthesia and permanent implants the company has also expanded options for women with its two commercially available products for diagnosis of infertility femvue® salineair device and cervical cancer femcerv® endocervical sampler that present significant advantages for the patient physician and healthcare system we are pleased to have the support and confidence of this esteemed group of investors said kathy leesepsick femasys president and ceo this round of funding will enable femasys to invest in the people and programs necessary to achieve the investigational device exemption ide milestone for fembloc and expand commercialization globally for our diagnostic products to allow women access to better options when it comes to managing their health needs femasys fills an important and significant gap in the womens healthcare continuum said john q adams jr legacy capital partners we believe that both physicians and patients will have great interest in the innovative new technologies and that we can provide value to the company through our highly experienced investor syndicate about legacy capital partners john adams jr was the former ceo of adams respiratory therapeutics developer of the mucinex brands adams was sold to reckitt benckiser in  for  billion mr adams has been in the pharmaceutical industry for over  years and has made investments in a number of developmentstage companies legacy capital partners is based in southlake tx about mario family partners mario family partners is the private equity arm of dr ernest marios family office dr mario was the former ceo of alza corporation which was sold to johnson  johnson for  billion in  the largestever ma deal for jj at the time he was previously ceo of glaxo and currently sits on the boards of boston scientific corporation and celgene corporation among others about salem partners llc  wwwsalempartnerscom salem partners is a boutique investment bank and wealth management firm based in los angeles that specializes in raising growth capital and executing ma assignments for companies in the media life sciences and industrial sectors salem has a strong track record in life sciences having raised substantially all of the private capital for adams respiratory therapeutics zs pharma inc and neos therapeutics femasys appoints fred aslan and charles larsen to its board of directors ×  aslan and larsen are seasoned healthcare executives who have successfully developed emerging technologies to advance the practice of medicine  atlanta ga march    femasys inc a developer of innovative medical devices for the womens healthcare market today announced that fred aslan founder and chief executive officer of advance medical inc and vice president of venrock and charles e larsen managing director of accuitive medical ventures have been appointed to the femasys board of directors both new directors bring significant leadership operations and commercial experience to femasys as the company prepares to commence its pivotal trial of fembloc™ which is designed to provide women with the first nonsurgical permanent contraception option delivered exclusively in the office we are extremely honored to have fred and charlie join our board of directors – they are proven executives who have been successful starting new businesses developing and commercializing emerging technologies building organizations and delivering value to shareholders” said kathy leesepsick president and ceo of femasys “their considerable experience will be invaluable to our team as we embark on the next phase of development with fembloc™” dr aslan has over  years of strategic management and direct investment experience in the medical device diagnostics and biotechnology sectors dr aslan is currently the founder and chief executive officer of advance medical a venrock portfolio company that is focused on the commercialization of medical device and diagnostics technologies in brazil and he is also a vice president at venrock dr aslan has served on the board of directors of receptos a company recently acquired by celgene and has been a board observer for a number of other companies including zeltiq and powervision dr aslan was the director of business development and investor relations at curagen corporation prior to curagen he worked at boston consulting group where he advised biotechnology and pharmaceutical companies on a number of strategic initiatives dr aslan received his bs in biology from duke university md from yale university school of medicine and mba from the harvard business school mr larsen has over  years of operating and technical experience in the medical device industry he cofounded novoste corporation and the innovation factory and through his role at the innovation factory he cofounded additional companies including acufocus aquesys halscion liposonix neuronetics and sebacia he holds over  issued us and international patents on medical devices before joining novoste mr larsen held positions with novoste puerto rico cordis corporation key pharmaceuticals and parkedaviswarner lambert in executive senior engineering and project management roles mr larsen received a bs in mechanical engineering from the new jersey institute of technology mr larsen currently is member of the board of directors for acufocus cardiofocus intuity and torax about femasys femasys inc based in atlanta ga is a privately held corporation committed to transforming womens healthcare worldwide by expanding options for women with innovative medical devices and next generation advancements providing significant clinical impact additional information about femasys and the company’s products can be found at wwwfemasyscom femasys has developed a groundbreaking nonsurgical female sterilization device fembloc™ permanent contraceptive system that allows physicians to deliver exclusively in their office a biopolymer through a catheterbased delivery system to permanently block the fallopian tubes in a procedure that substantially reduces patient risks and costs by eliminating the use of anesthesia and permanent implants the company has also expanded options for women with its two commercially available products for diagnosis of infertility femvue® salineair device and cervical cancer femcerv® endocervical sampler that present significant advantages for the patient physician and healthcare system femasys announces  million in series c financing to complete development of fembloc™ funding to support pivotal testing of nonsurgical permanent contraception solution fembloc™   ide approval granted by fda for us clinical trial of fembloc study to start early 7  × atlanta dec   globe newswire  femasys inc a developer of innovative medical devices for the womens healthcare market today announced that it has closed  million in series c financing the transaction was arranged by salem partners a los angelesbased investment bank which also participated as a principal investor the series c syndicate included multiple institutional investors family offices and a multibilliondollar global medical device company the funding will be used primarily to support the pivotal testing of fembloc™ the companys revolutionary nonsurgical permanent contraception solution femasys designed fembloc to provide women with the first nonsurgical permanent contraceptive option delivered exclusively in the physicians office we are thrilled with the level of enthusiasm in this oversubscribed round of funding and grateful for the backing from our new and existing investors said kathy leesepsick femasys president and ceo their financial investment enables us to conduct and complete the fembloc clinical plan which will support our planned premarket approval application pma and ultimately our vision of improving the lives of women by providing access to an ideal permanent contraception solution that is safe and highly effective for women in the us and worldwide femasys also announced that it has gained us food and drug administration fda investigational device exemption ide approval to launch a prospective multicenter clinical trial to evaluate the safety of the fembloc permanent contraceptive system while preventing pregnancy the clinical trial which will enroll women who desire permanent birth control by occlusion of the fallopian tubes will be the companys first trial to evaluate the complete fembloc contraceptive system for its intended use fembloc is designed to fill the unmet need of a safe permanent contraceptive method that can be easily implemented since it does not require specialized surgical skills or investment in costly surgical equipment said mimi zieman md vice president of clinical affairs at femasys and a board certified obgyn specializing in family planning this contrasts with current female sterilization options that have the inconvenience and risks associated with surgery and anesthesia for tubal ligation and for hysteroscopic procedures  the challenge of placing the devices correctly and concerns with longterm use dechert llp served as legal counsel to femasys inc while baker botts llp served as investor counsel about femasys femasys is a privately held corporation committed to transforming womens healthcare worldwide by expanding options for women with innovative medical devices and next generation advancements providing significant clinical impact additional information about femasys and the companys products can be found at wwwfemasyscom femasys has developed a groundbreaking nonsurgical female sterilization solution fembloc™ permanent contraceptive system that allows physicians to deliver exclusively in their office a biopolymer through a catheterbased delivery system to permanently block the fallopian tubes in a procedure that substantially reduces patient risks and costs by eliminating the use of anesthesia and permanent implants the company has also expanded options for women with its two commercially available products for diagnosis of infertility femvue® salineair device and cervical cancer femcerv® endocervical sampler that present significant advantages for the patient physician and healthcare system fembloc permanent contraceptive system is not commercially available for sale femasys fembloc femvue and femcerv are registered trademarks of femasys inc all rights reserved terms  privacy × this site and any related services are provided subject to these terms and conditions please read the following information carefully your continued use of this website will indicate your agreement to be bound by the terms and conditions set forth belowif you do not wish to be bound by these terms and conditions please do not use or access this website femasys may modify the terms and conditions at any time and such modifications will be effective immediately upon posting to the website please review the terms of use and privacy policy each time you visit the femasys website purpose this is a world wide web site for information about femasys inc products fembloc femcerv and femvue and sono hsg the purpose is to provide information to healthcare providers patients and all interested parties copyright all rights including copyright in the content of the web pages contained in this website are owned or controlled for these purposes by femasys inc in accessing femasys web pages you agree that you may only download the content for your personal noncommercial use you are not permitted to copy reproduce republish distribute broadcast download store in any medium transmit show or play in public adapt or change in any way the content of these femasys web pages for any other purpose whatsoever without the prior written permission of femasys inc security unauthorized attempts to upload information or change information on this web site are strictly prohibited and may be punishable under the computer fraud and abuse act of  and the national information infrastructure protection act for site security purposes and to ensure that this service remains available to all users this server employs software programs to monitor network traffic to identify unauthorized attempts to upload or change information or otherwise cause damage trademark notice femasys is a trademark of femasys inc other trademarks logos brand names and slogans registered or used by femasys in the united states andor other countries include but are not limited to the following fembloc femcerv femchec femaseed and femvue all other trademarks and registered trademarks are the property of their respective owners privacy policyexcept to maintain required correspondence files no other attempts are made to identify individual users or their usage habits raw data logs are used to determine how many users are accessing the site which pages are most popular and from time to time from which top level domain users are coming no personally identifying information about you will be obtained when you visit this site unless you choose to provide such information to us if you choose to send an email to points of contact on the site any information you provide will be used solely to respond to your request yelp yelp sorry you’re not allowed to access this page contact yelp if you keep experiencing issues bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one